Format

Send to

Choose Destination
PLoS One. 2017 Jul 31;12(7):e0182030. doi: 10.1371/journal.pone.0182030. eCollection 2017.

C77G in PTPRC (CD45) is no risk allele for ovarian cancer, but associated with less aggressive disease.

Author information

1
Centre for Molecular Medicine Norway, Nordic EMBL Partnership, University of Oslo and Oslo University Hospital, Oslo, Norway.
2
K.G. Jebsen Centre for Cancer Immunotherapy, University of Oslo, Oslo, Norway.
3
Department of Molecular Oncology, Institute for Cancer Research, Oslo University Hospital, The Norwegian Radium Hospital, Oslo, Norway.
4
Center for Cancer Biomedicine, Faculty of Medicine, University of Oslo, Oslo, Norway.
5
K.G. Jebsen Colorectal Cancer Research Centre, Oslo University Hospital, Oslo, Norway.
6
Department of Pathology, Haukeland University Hospital, Bergen, Norway.
7
Centre for Cancer Biomarkers CCBIO, Department of Clinical Medicine, Section for Pathology, University of Bergen, Bergen, Norway.
8
Department of Gynaecologic Oncology, Oslo University Hospital, The Norwegian Radium Hospital, Oslo, Norway.
9
Norwegian PSC Research Centre, Department of Transplantation Medicine, Division of Surgery, Inflammatory Medicine and Transplantation, Oslo University Hospital, The National Hospital, Oslo, Norway.
10
K.G. Jebsen Inflammation Research Centre, University of Oslo, Oslo, Norway.
11
Department of Obstetrics and Gynaecology, Haukeland University Hospital, Bergen, Norway.
12
Department of Clinical Science, Centre for Cancer Biomarkers, University of Bergen, Bergen, Norway.

Abstract

The pan lymphocyte marker CD45 exists in various isoforms arising from alternative splicing of the exons 4, 5 and 6. While naïve T cells express CD45RA translated from an mRNA containing exon 4, exons 4-6 are spliced out to encode the shorter CD45R0 in antigen-experienced effector/memory T cells. The SNP C77G (rs17612648) is located in exon 4 and blocks the exon's differential splicing from the pre-mRNA, enforcing expression of CD45RA. Several studies have linked C77G to autoimmune diseases but lack of validation in other cohorts has left its role elusive. An incidental finding in an ovarian cancer patient cohort from West Norway (Bergen region, n = 312), suggested that the frequency of C77G was higher among ovarian cancer patients than in healthy Norwegians (n = 1,357) (3.0% vs. 1.8% allele frequency). However, this finding could not be validated in a larger patient cohort from South-East Norway (Oslo region, n = 1,198) with 1.2% allele frequency. Hence, C77G is not associated with ovarian cancer in the Norwegian population. However, its frequency was increased in patients with FIGO stage II, endometrioid histology or an age at diagnosis of 60 years or older indicating a possible association with a less aggressive cancer type.

PMID:
28759630
PMCID:
PMC5536273
DOI:
10.1371/journal.pone.0182030
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Public Library of Science Icon for PubMed Central
Loading ...
Support Center